![ATR inhibition enhances 5-fluorouracil sensitivity independent of non-homologous end-joining and homologous recombination repair pathway | bioRxiv ATR inhibition enhances 5-fluorouracil sensitivity independent of non-homologous end-joining and homologous recombination repair pathway | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2020/04/20/2020.04.20.051318/F1.large.jpg)
ATR inhibition enhances 5-fluorouracil sensitivity independent of non-homologous end-joining and homologous recombination repair pathway | bioRxiv
Package leaflet: Information for the user Fluorouracil 50 mg/ml Solution for injection or infusion Fluorouracil Read all of thi
![Tumor-Specific Delivery of 5-Fluorouracil–Incorporated Epidermal Growth Factor Receptor–Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models - ScienceDirect Tumor-Specific Delivery of 5-Fluorouracil–Incorporated Epidermal Growth Factor Receptor–Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S001650852103081X-fx1.jpg)
Tumor-Specific Delivery of 5-Fluorouracil–Incorporated Epidermal Growth Factor Receptor–Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models - ScienceDirect
![Cancers | Free Full-Text | Cytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2 Cancers | Free Full-Text | Cytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2](https://www.mdpi.com/cancers/cancers-10-00373/article_deploy/html/images/cancers-10-00373-g001.png)
Cancers | Free Full-Text | Cytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2
A Ham1p-Dependent Mechanism and Modulation of the Pyrimidine Biosynthetic Pathway Can Both Confer Resistance to 5-Fluorouracil in Yeast | PLOS ONE
![A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo | Journal of Medicinal Chemistry A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.1c01733/asset/images/large/jm1c01733_0001.jpeg)
A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo | Journal of Medicinal Chemistry
![5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration | ONS 5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration | ONS](https://cjon.ons.org/sites/default/files/journal-images/BrutcherDecember2018Table2.png)
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration | ONS
![5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration | ONS 5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration | ONS](https://cjon.ons.org/sites/default/files/journal-images/BrutcherDecember2018Figure2.png)
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration | ONS
![5-Fluorouracil Induces Enteric Neuron Death and Glial Activation During Intestinal Mucositis via a S100B-RAGE-NFκB-Dependent Pathway | Scientific Reports 5-Fluorouracil Induces Enteric Neuron Death and Glial Activation During Intestinal Mucositis via a S100B-RAGE-NFκB-Dependent Pathway | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-018-36878-z/MediaObjects/41598_2018_36878_Fig1_HTML.png)
5-Fluorouracil Induces Enteric Neuron Death and Glial Activation During Intestinal Mucositis via a S100B-RAGE-NFκB-Dependent Pathway | Scientific Reports
![DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update - Annals of Oncology DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/fe71302f-42fb-418c-bb43-94e239cbc26f/gr1.jpg)